pf-514273 and Obesity

pf-514273 has been researched along with Obesity* in 1 studies

Other Studies

1 other study(ies) available for pf-514273 and Obesity

Article	Year
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9 We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB(1)) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB(1) antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management. Topics: Animals; Clinical Trials as Topic; Crystallography, X-Ray; Drug Discovery; Humans; Lactams; Obesity; Oxazepines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1	2009

Article

Year

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB(1)) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB(1) antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management.

Topics: Animals; Clinical Trials as Topic; Crystallography, X-Ray; Drug Discovery; Humans; Lactams; Obesity; Oxazepines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1

2009